Changes in cardiac and vascular haemodynamics as potential mediators of improvements in cardiovascular and kidney outcomes with empagliflozin in type 2 diabetesBernhard K. Krämer, Christoph Wanner, Robert Ćhilton et al.|Journal of Diabetes and its Complications|2023Cited by 6